

## S&P 500 Pharmaceuticals Company

### Introduction

This case study of a S&P 500 pharmaceuticals company is based on a June 2021 survey of Prevalent customers by TechValidate, a 3rd-party research service. The profiled company asked to have their name blinded to protect their confidentiality.



“It has enhanced it and reduced turnaround times immensely.”

### Challenges

- Their primary vendor risk assessment pain points were:
  - Too much time spent manually onboarding new vendors
  - Complex, manual assessment processes (e.g., using spreadsheets)

### Use Case

- Currently assessing their vendors for the following:
  - Cybersecurity

### Results

- Level of agreement:
  - Prevalent provides the inherent risk visibility they need to focus on specific areas of their vendors' risks: strongly agree
  - Prevalent provides the real-time cybersecurity, reputational and financial intelligence they need: agree
- Prevalent is critical on the following vendor lifecycle stages:
  - Intake and vendor onboarding: essential  
\*\*Scoring inherent risks: very Important
  - Assessing vendors and remediating risks: critical
- Strongly agree with the following:
  - Prevalent allows us to do our job more effectively
  - Prevalent's vendor risk assessment process is invaluable to our group
  - Prevalent reduced the time and complexity required to perform vendor risk assessments
- We have realized major cost savings with Prevalent's vendor risk management process.: agree

#### Company Profile

The company featured in this case study asked to have its name publicly blinded because publicly endorsing vendors is against their policies.

TechValidate stands behind the authenticity of this data.

Company Size:  
**S&P 500**

Industry:  
**Pharmaceuticals**

#### About Prevalent

Prevalent is helping global organizations manage and monitor the security threats and risks associated with third and fourth-party vendors.

#### Learn More:

[Prevalent](#)